[1. Garlanda C, Dinarello CA, Mantovani A. The interleukin – 1 family: back to the future. Immunity. 2013;39(6):1003-1018.10.1016/j.immuni.2013.11.010393395124332029]Open DOISearch in Google Scholar
[2. Günther S et al. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity. 2017 19;47(3):510-52310.1016/j.immuni.2017.08.004584908528930661]Search in Google Scholar
[3. Wasmer M-H, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Frontiers in Immunology. 2016;7:682.10.3389/fimmu.2016.00682]Search in Google Scholar
[4. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 2011;15;187(4):1609-16.10.4049/jimmunol.100308021734074]Search in Google Scholar
[5. Gadina M, Jefferies CA. IL-33: a sheep in wolf’s clothing? Sci STKE. 2007 Jun 12;2007:390.10.1126/stke.3902007pe3117565120]Search in Google Scholar
[6. Gao X et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015 Jan 1;194(1):438-4510.4049/jimmunol.1401344427290125429071]Search in Google Scholar
[7. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med; 2016;94(5):535-432692261810.1007/s00109-016-1397-026922618]Search in Google Scholar
[8. Dominguez D et al. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. Immunol. 2017 1;198(3):1365-137510.4049/jimmunol.1501399526311328011934]Search in Google Scholar
[9. Amôr NG et al. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget. 2018 Jul 20;9(56):30894-30904.10.18632/oncotarget.25768608939930112116]Search in Google Scholar
[10. Lin SH et al. Inflammation elevated IL-33 originating from the lung mediates inflammation in acute lung injury. Clin Immunol; 2016; 30535-6.10.1016/j.clim.2016.10.01427989898]Search in Google Scholar
[11. Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B, Zhu Y. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018 2;13(3).10.1371/journal.pone.0193428583417529499051]Search in Google Scholar
[12. Chen J et al. Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells. Front Immunol. 2018 31;9:1787.10.3389/fimmu.2018.01787607924230108595]Search in Google Scholar
[13. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. (2011) ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 41: 1902–1912.10.1002/eji.201141417374612721484786]Open DOISearch in Google Scholar
[14. Zhang Y et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog 56: 272–287.10.1002/mc.22491563013627120577]Search in Google Scholar
[15. Ishikawa K et al. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx. 2014 Dec;41(6):552-7.10.1016/j.anl.2014.08.00725193287]Open DOISearch in Google Scholar
[16. Chen SF et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013 Oct;231(2):180-9.10.1002/path.422623775566]Search in Google Scholar
[17. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med 94: 535–543.10.1007/s00109-016-1397-026922618]Search in Google Scholar
[18. Li J et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014; 124(7):3241-51.10.1172/JCI73742407137024892809]Search in Google Scholar
[19. Zhang JF et al. IL33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol Rep. 2017 Oct;38(4):2033-2042.10.3892/or.2017.5926565295128849217]Open DOISearch in Google Scholar
[20. Xiao P et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2015. 24;5(1)10.1080/2162402X.2015.1063772476033826942079]Search in Google Scholar
[21. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBOJ. 1992 (11):3887-9510.1002/j.1460-2075.1992.tb05481.x]Search in Google Scholar
[22. Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018 22;50(8):109.10.1038/s12276-018-0130-1610567430135516]Search in Google Scholar
[23. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219-242.10.1111/j.1600-065X.2010.00923.x291927520636820]Search in Google Scholar
[24. Ortler S et al. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol. 2008;38(6):1734-4410.1002/eji.20073807118421793]Search in Google Scholar
[25. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153-16710.1038/nri.2017.10828990585]Search in Google Scholar
[26. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-477.10.1038/nri232618500231]Search in Google Scholar
[27. Gupta PK et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog. 2015;11(10):e1005177.10.1371/journal.ppat.1005177461899926485519]Search in Google Scholar
[28. Starr R et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997; 387: 917-921.10.1038/432069202125]Search in Google Scholar
[29. Massari F et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015; 41: 114-121.10.1016/j.ctrv.2014.12.01325586601]Search in Google Scholar
[30. Ahmad SM et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncoimmunology. 2017;7(2): e1390641.10.1080/2162402X.2017.1390641574966929308318]Search in Google Scholar
[31. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-42.10.1111/j.1600-065X.2010.00923.x]Search in Google Scholar
[32. Reynolds J et al. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2012 Apr;27(4):1343-50.10.1093/ndt/gfr52921965585]Search in Google Scholar
[33. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677–704.10.1146/annurev.immunol.26.021607.09033118173375]Search in Google Scholar
[34. White MPJ, Webster G, Leonard F, La Flamme AC. Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression. Sci Rep. 2018 Jan 10;8(1):259.10.1038/s41598-017-18543-z576289129321652]Search in Google Scholar
[35. Rowe JH, Ertelt JM, Way SS. Innate IFN-γ is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection. J Immunol. 2012;189(2):876-84.10.4049/jimmunol.1103227340234222711893]Search in Google Scholar
[36. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009; 229: 114-125.10.1111/j.1600-065X.2009.00767.x342406619426218]Search in Google Scholar
[37. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001; 98: 13866-13871.10.1073/pnas.2314865986113311698646]Search in Google Scholar
[38. Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M. Overcoming tumor-mediated immunosuppression. Immunotherapy., 2014; 6: 973-98810.2217/imt.14.58]Search in Google Scholar
[39. Chen X et al. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol. 2014; 44: 2603-2616.10.1002/eji.201344423416570124975127]Search in Google Scholar
[40. Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. J Cancer. 2018;9(16):2938-2945.10.7150/jca.22532609636430123362]Search in Google Scholar
[41. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-504.10.1093/annonc/mdw21727207108]Search in Google Scholar
[42. Taube JM et al. Colocalization o inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012 28;4(127):12710.1126/scitranslmed.3003689356852322461641]Search in Google Scholar
[43. Cheng B, Yuan WE, Su J, Liu Y, Chen J. Recent advances in small molecule based cancer immunotherapy. Eur J Med Chem. 2018;157:582-598.10.1016/j.ejmech.2018.08.02830125720]Search in Google Scholar
[44. Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014 Oct 15;193(8):3835-41.10.4049/jimmunol.1401572418542525281753]Search in Google Scholar
[45. Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13): 1270-1.10.1056/NEJMc150966026398076]Search in Google Scholar
[46. Roger A et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology. 2018;7(7): e1442166.10.1080/2162402X.2018.1442166605330030034949]Search in Google Scholar
[47. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-9.2346241910.1016/j.ijrobp.2012.12.025396340323462419]Search in Google Scholar
[48. Choi N, Shin DY, Kim HJ, Moon UY, Baek KH, Jeong HS. Postoperative anti-PD-1 antibody treatment to reduce recurrence in a cancer ablation surgical wound. J Surg Res. 2018;221:95-103.10.1016/j.jss.2017.08.02229229160]Search in Google Scholar
[49. Qin L et al. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016;7(38):61069-61080.10.18632/oncotarget.11179530863627517629]Search in Google Scholar
[50. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012 1;12(4):307-13.10.1038/nrc3246355260922378190]Open DOISearch in Google Scholar